The average one-year price target for Athira Pharma (NasdaqCM:ATHA) has been revised to $4.08 / share. This is an increase of 700.00% from the prior estimate of $0.51 dated September 10, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $4.04 to a high of $4.20 / share. The average price target represents an increase of 4.08% from the latest reported closing price of $3.92 / share.
What is the Fund Sentiment?
There are 37 funds or institutions reporting positions in Athira Pharma. This is an decrease of 28 owner(s) or 43.08% in the last quarter. Average portfolio weight of all funds dedicated to ATHA is 0.17%, an increase of 427.80%. Total shares owned by institutions decreased in the last three months by 91.12% to 1,715K shares. 
The put/call ratio of ATHA is 0.01, indicating a bullish outlook.
What are Other Shareholders Doing?
Perceptive Advisors holds 540K shares representing 13.70% ownership of the company. No change in the last quarter.
BML Capital Management holds 323K shares representing 8.19% ownership of the company.
Propel Bio Management holds 149K shares representing 3.79% ownership of the company.
Simplify Asset Management holds 149K shares representing 3.79% ownership of the company. No change in the last quarter.
Tang Capital Management holds 60K shares representing 1.52% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
